3,305
Total Claims
$994K
Drug Cost
464
Beneficiaries
$2,143
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+41%
Cost per patient vs peers
$2,143 vs $1,524 avg
+51%
Brand preference vs peers
20.6% vs 13.7% avg
Brand vs Generic
79% generic
Brand: 681 claims · $921K
Generic: 2,624 claims · $73K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 173 | $194K |
| Sacubitril/Valsartan | 124 | $178K |
| Empagliflozin | 121 | $154K |
| Mavacamten | 15 | $128K |
| Rivaroxaban | 43 | $61K |
| Tirzepatide | 34 | $45K |
| Semaglutide | 24 | $37K |
| Icosapent Ethyl | 41 | $34K |
| Evolocumab | 31 | $29K |
| Alirocumab | 32 | $28K |
| Rosuvastatin Calcium | 482 | $13K |
| Icosapent Ethyl | 36 | $13K |
| Ezetimibe | 166 | $5,298 |
| Ranolazine | 24 | $3,993 |
| Metoprolol Succinate | 185 | $3,523 |
Prescribing Profile
Patient Profile
77
Avg Age
56%
Female
1.76
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About